• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ANAKINRA Drug Record

  • Summary
  • Interactions
  • Claims
  • ANAKINRA chembl:CHEMBL1201570 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    KINERET
    ANTRIL
    ANAKINRA
    INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN PRECURSOR
    IL1 INHIBITOR
    ICIL-1RA
    IL-1RN
    IRAP
    IL-1RA
    drugbank:00026
    chemidplus:143090-92-0
    rxcui:72435
    chembl:CHEMBL1201570

    Drug Info:

    FDA Approval approved
    Drug Class recombinant protein
    Drug Indications antiinflammatory agent,DMARD
    Drug Class antirheumatic agents
    Year of Approval 2003
    (4 More Sources)

    Publications:

    Vannier et al., 1999, Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy., Eur. Cytokine Netw.
    So et al., 2007, A pilot study of IL-1 inhibition by anakinra in acute gout., Arthritis Res. Ther.
    Do et al., 2006, Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort., J. Infect. Dis.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Tang et al., 2007, [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats]., Zhong Xi Yi Jie He Xue Bao
    Vamvakopoulos et al., 2002, Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist., Eur. J. Immunol.
    Dayer, 2003, The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis., Rheumatology (Oxford)
    Haq et al., 1998, Role of IL-1 in renal ischemic reperfusion injury., J. Am. Soc. Nephrol.
    Dhar et al., 1997, Interleukin-1 alpha upregulates the expression of surfactant protein-A in rabbit lung explants., Biol. Neonate
    Sun et al., 1996, Protective effect of interleukin-1 receptor antagonist on oleic acid-induced lung injury., Chin. Med. J.
    Hawkins et al., 2004, Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra., Arthritis Rheum.
    Bevan et al., 1991, IL-1 receptor antagonist regulation of acute phase protein synthesis in human hepatoma cells., J. Immunol.
    Damtew et al., 1993, IL-1 receptor antagonist affects the plasma protein response of Hep 3B cells to conditioned medium from lipopolysaccharide-stimulated monocytes., J. Immunol.
    Wang et al., 2006, LPS inhibits fasted plasma ghrelin levels in rats: role of IL-1 and PGs and functional implications., Am. J. Physiol. Gastrointest. Liver Physiol.
  • ANAKINRA   IL1R1

    Interaction Score: 16.75

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Interleukin-1 receptor antagonist
    Direct Interaction yes
    Trial Name anakinra,Kineret

    PMIDs:
    10210771 17352828 17083033 11752352 17498496 12355453 12817089 9555664


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND TTD

  • ANAKINRA   SAA1

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1717568


    Sources:
    NCI

  • ANAKINRA   IL1R2

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • ANAKINRA   SFTPA1

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8996657


    Sources:
    NCI

  • ANAKINRA   NLRP3

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14872505


    Sources:
    NCI

  • ANAKINRA   GHRL

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16959954


    Sources:
    NCI

  • ANAKINRA   CP

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7682588


    Sources:
    NCI

  • ANAKINRA   NOS1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9206098


    Sources:
    NCI

  • TEND: ANAKINRA

    • Version: 01-August-2011

    Alternate Names:
    ANAKINRA Primary Drug Name

    Drug Info:
    Year of Approval 2003
    Drug Class antirheumatic agents

    Publications:

  • TdgClinicalTrial: ANAKINRA

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,DMARD
    Drug Class recombinant protein
    FDA Approval approved

    Publications:

  • NCI: IL-1RA

    • Version: 14-September-2017

    Alternate Names:
    C2486 NCI drug code

    Drug Info:

    Publications:
    Haq et al., 1998, Role of IL-1 in renal ischemic reperfusion injury., J. Am. Soc. Nephrol.
    Wang et al., 2006, LPS inhibits fasted plasma ghrelin levels in rats: role of IL-1 and PGs and functional implications., Am. J. Physiol. Gastrointest. Liver Physiol.
    Sun et al., 1996, Protective effect of interleukin-1 receptor antagonist on oleic acid-induced lung injury., Chin. Med. J.

  • NCI: ANAKINRA

    • Version: 14-September-2017

    Alternate Names:
    C38717 NCI drug code

    Drug Info:

    Publications:
    Hawkins et al., 2004, Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra., Arthritis Rheum.

  • TTD: Anakinra

    • Version: 2020.06.01

    Alternate Names:
    D02DES TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201570

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201570

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: ANAKINRA

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21